Findings detected by the AI software are shown in colour as a heatmap display, with each score included
Fujifilm Corporation announced its AI-powered product for analyzing chest X-ray ‘CXR-AID’ will be commercially available across Japan. CXR-AID is designed to better detect major abnormal findings such as chest nodule, consolidation, and pneumothorax from chest X-ray images. Findings detected by the AI software are shown in colour as a heatmap display, with each score included. Through this solution, doctors and medical professionals can reduce missed cases and effectively diagnose chest diseases from chest X-ray.
The PMDA approved AI-powered software is developed with the core AI technology of Lunit, the company’s solid partner since 2018. The software is provided with Fujifilm’s PACS system(SYNAPSE) and is to be distributed across hospitals and medical institutions of Japan for more efficient diagnosis. A leading medical AI company, Lunit provides deep-learning-based AI technology called ‘Lunit INSIGHT CXR‘ that analyses chest X-rays.
With Lunit AI connected to Fujifilm’s PACS system and X-ray devices, the AI products are distributed across its global customers and networks. The company has also invested in Lunit as a strategic investor.
“We strongly believe that sooner or later AI will become the new standard of care, and AI will be used everywhere as a must-use product,” added Suh. “Not only will it be used as a tool to make the workflow more efficient, but it will ensure better diagnosis and healthier life for patients. We are glad to make this happen with Fujifilm, and will accelerate our expansion with its global network.”